Skip to content
Home » Viatris forecasts strong 2024 sales on higher demand for branded drugs

Viatris forecasts strong 2024 sales on higher demand for branded drugs

    Viatris was formed with the merger of Mylan and Pfizer's Upjohn business and has generic and key branded drugs in its portfolio, including erectile dysfunction drug Viagra, anti-anxiety medication Xanax, epilepsy treatment Lyrica and arthritis treatment Celebrex. CEO Scott Smith said Viatris would focus on growing its base business, which consists of its generic and branded drugs portfolio, this year, including through research partnerships such as its deal with Switzerland-based biotech Idorsia that was announced earlier on Wednesday.

    Read full NASCAR article on Yahoo Sports

    Read all NASCAR articles